BWX Technologies, Inc.

BWX Technologies, Inc. (BWXT) Market Cap

BWX Technologies, Inc. has a market capitalization of $21.60B.

Financials based on reported quarter end 2025-12-31

Price: $235.78

4.98 (2.16%)

Market Cap: 21.60B

NYSE · time unavailable

CEO: Rex D. Geveden

Sector: Industrials

Industry: Aerospace & Defense

IPO Date: 2010-08-02

Website: https://www.bwxt.com

BWX Technologies, Inc. (BWXT) - Company Information

Market Cap: 21.60B · Sector: Industrials

BWX Technologies, Inc. manufactures and sells nuclear components in the United States, Canada, and internationally. It operates in three segments: Nuclear Operations Group, Nuclear Power Group, and Nuclear Services Group. The Nuclear Operations Group segment provides precision naval and critical nuclear components, reactors, nuclear fuel, and assemblies for the United States Department of Energy/National Nuclear Security Administration's Naval Nuclear Propulsion Program and other uses; missile launch tubes for United States Navy submarines; close-tolerance and equipment for nuclear applications; and converts Cold War-era government stockpiles of high-enriched uranium, as well as receives, stores, characterizes, dissolves, recovers, and purifies uranium-bearing materials; supplies research reactor fuel elements for colleges, universities, and national laboratories; and components for defense applications. The Nuclear Power Group segment offers commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and containers; engineering and in-plant services for nuclear power plants; designs, manufactures, commissions, and services nuclear power generation equipment; in-plant inspection, maintenance, and modification services, as well as non-destructive examination and tooling/repair solutions; and supplies medical radioisotopes and radiopharmaceuticals for research, diagnostic, and therapeutic uses. The Nuclear Services Group segment provides nuclear materials processing, environmental site restoration, and management and operating services; develops technology for nuclear power sources application; and designs, engineers, licenses, and manufactures nuclear reactors. The company was formerly known as The Babcock & Wilcox Company and changed its name to BWX Technologies, Inc. in June 2015. BWX Technologies, Inc. was founded in 1867 and is headquartered in Lynchburg, Virginia.

Analyst Sentiment

69%
Buy

Based on 14 ratings

Analyst 1Y Forecast: $193.67

Average target (based on 3 sources)

Consensus Price Target

Low

$195

Median

$210

High

$225

Average

$210

Downside: -10.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 BWX TECHNOLOGIES INC (BWXT) — Investment Overview

🧩 Business Model Overview

BWX Technologies Inc (BWXT) operates as a strategic supplier of nuclear components and services primarily supporting defense and energy sectors. The company’s core business encompasses the design, engineering, manufacture, and service of nuclear systems for naval nuclear propulsion, commercial nuclear power, medical isotopes, and various government and defense applications. Its vertically integrated operations include highly specialized manufacturing facilities with unique licenses and quality credentials, supporting the entire value chain from R&D to decommissioning. BWXT’s focus on nuclear technology establishes deep barriers to entry and recurring contracts with governmental and regulated customers, particularly the U.S. Department of Energy (DOE) and the U.S. Department of Defense (DoD), fostering stable long-term relationships and significant visibility.

💰 Revenue Streams & Monetisation Model

BWXT’s revenue model is diversified across several core operating segments: - **Nuclear Operations Group (NOG):** The largest contributor, providing nuclear reactor components and fuel for U.S. Navy submarines and aircraft carriers under multi-year, cost-plus and fixed-price contracts. This division also supplies materials and technical services for DOE facilities. - **Nuclear Power Group (NPG):** Serving commercial nuclear power markets, this segment manufactures specialized components, fuel, and services for reactors globally, with offerings in plant life extension, refurbishment, and reactor decommissioning. - **Nuclear Services Group (NSG):** Delivers management, technical, and operational services for federal sites involved in nuclear materials handling, cleanup, waste management, and site remediation. - **Advanced Technologies & Isotopes:** Driven by innovation, this segment focuses on nuclear medicine, radioisotopes, and prototype/reactor solutions for both government and private sectors. The company’s monetisation approach is underpinned by long-duration contracts, recurring maintenance agreements, and performance incentives. Government and utility customers provide stable, countercyclical revenue streams, while specialty isotope sales and new-build engineering are emerging incremental revenue opportunities.

🧠 Competitive Advantages & Market Positioning

BWXT’s competitive position is anchored by several structural advantages: - **Regulatory Licensing and Technical Expertise:** As one of the limited suppliers licensed to produce U.S. naval nuclear reactors, BWXT enjoys a unique competitive moat. The company’s facilities, skilled workforce, and proprietary processes are difficult to replicate, requiring years of regulatory compliance and capital investment. - **Entrenched Customer Base:** BWXT’s long-standing relationships with government agencies create significant switching costs and ensure contract renewal opportunities. - **Scale and Integration:** Vertical integration from fuel processing to component assembly provides cost controls, quality assurance, and schedule reliability, giving BWXT a preferred status for mission-critical work. - **Technology and Innovation:** Investments in advanced reactors, modular nuclear solutions, and medical isotopes position the company at the forefront of both defense and commercial nuclear innovation. - **Reputational Capital:** Decades of safe and reliable nuclear component delivery build reputation-based barriers to entry that extend across defense and civilian markets.

🚀 Multi-Year Growth Drivers

BWXT’s growth outlook is supported by several durable, structural tailwinds: - **U.S. Defense Modernization:** Significant capital committed to naval nuclear fleet modernization—particularly submarine and aircraft carrier programs—drive sustained demand for BWXT’s reactors and nuclear fuel. - **Nuclear Energy Resurgence:** Global decarbonization priorities and energy security concerns are catalyzing renewed interest in nuclear power, including plant life extension, uprate projects, and new reactor orders. - **Medical Isotopes and Radiopharmaceuticals:** Rising demand for medical isotopes for diagnostic imaging and cancer treatment underpin expansion opportunities in the healthcare vertical. - **Advanced and Small Modular Reactors (SMRs):** Investment and regulatory momentum behind next-generation reactor technologies represent new addressable markets for BWXT’s engineering and manufacturing expertise. - **International Expansion:** Emerging market nuclear programs and allied defense needs offer opportunities for international contracts and new joint ventures. - **Waste Management and Nuclear Services:** Greater focus on legacy site cleanup, waste remediation, and decommissioning provides recurring, countercyclical service revenues.

⚠ Risk Factors to Monitor

Key risks to the investment case include: - **Government Funding and Policy Risk:** BWXT’s reliance on U.S. government defense budgets and policy creates exposure to political and budgetary cycles, with potential for contract delays or reductions. - **Nuclear Market Sentiment:** Nuclear power remains subject to regulatory changes, public opinion, and competitive pressures from renewables, potentially impacting new build activity. - **Execution and Program Risk:** Complex, bespoke manufacturing projects carry cost overruns or schedule delays that could erode margins and customer satisfaction. - **Supply Chain and Labor Constraints:** Limited availability of nuclear-grade materials and specialized labor could disrupt project timelines or increase input costs. - **Technical and Safety Incidents:** Given the hazardous nature of nuclear work, operational mishaps could have severe reputational, legal, or financial consequences. - **Customer Concentration:** High dependency on a small set of government customers increases vulnerability to contract changes or competitive bid losses.

📊 Valuation & Market View

BWXT is generally valued on the basis of its visible, long-term contracts, robust backlog, and defensible margins, characteristics highly prized in the defense and industrial infrastructure sectors. Investments in growth platforms such as medical isotopes and advanced reactors attract a premium for optionality and technological leadership. Peer comparisons may include defense industrials, nuclear utilities, and engineering services providers, though few have BWXT’s pure-play nuclear exposure. Investors often regard BWXT’s stable, inflation-protected government contracts and high free cash flow conversion as supportive of premium valuation multiples, particularly due to the defensive, countercyclical nature of its core revenue base. Potential upside scenarios involve greater penetration of the commercial nuclear resurgence, successful scaling in medical isotopes, or increased international contract wins. Conversely, slower-than-expected project ramp, regulatory shifts, or margin compression could justify more conservative valuation approaches.

🔍 Investment Takeaway

BWX Technologies Inc represents a unique, high-barrier play on the enduring demand for nuclear technology in both defense and civilian sectors. Its entrenched position as a sole-source supplier to the U.S. Navy and DOE, coupled with increasing opportunities in next-gen reactors and medical isotopes, underpin a compelling long-term investment thesis. Key attributes include resilient cash flows, strong pricing power, and significant optionality from innovation-led platforms. Risks related to government funding, execution, and nuclear market sentiment must be closely monitored, but BWXT’s combination of technical expertise, government relationships, and regulatory licenses offers considerable insulation. For investors seeking exposure to national security, energy transition, and healthcare innovation, BWXT stands out as a differentiated industrial business with defensive and secular growth characteristics.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"BWXT reported Q4 2025 revenue of approximately $886 million, achieving a net income of $93.8 million, which translated to an EPS of $1.02. The company sustained a net margin of around 10.6%. Despite an operational cash deficit, indicating challenges with cash generation, BWXT managed to pay regular dividends and repurchase shares. The balance sheet reveals total liabilities of approximately $3.04 billion against equity of $1.23 billion, resulting in a net debt position of $2.02 billion. Growth appeared tepid, likely constrained by industry-specific factors. Profitability was decent, supported by stable EPS, even though operating cash flow challenges exist—highlighting possible working capital or cost management issues. With significant liabilities, BWXT's balance sheet is moderately leveraged but within manageable limits due to a reasonable equity buffer. Shareholder returns included consistent dividend payments and stock buybacks, albeit exceeding free cash flow capacity, an area for cautious monitoring. Lastly, with a price target consensus at $204, there seems to be moderate optimism despite moderate financial strain."

Revenue Growth

Fair

Revenue showed slow growth, possibly due to sector conditions; key drivers require further detail.

Profitability

Neutral

Stable EPS and double-digit net margins demonstrate maintained profitability.

Cash Flow Quality

Neutral

Free cash flow is negative, impacted by operating losses; dividend and buyback practices strain cash flows.

Leverage & Balance Sheet

Fair

Net debt is significant but supported by equity; financial resilience is moderate.

Shareholder Returns

Good

Consistent dividends and buybacks, though not fully supported by cash flows. Strong stock performance on the 6M and 1Y timeframe

Analyst Sentiment & Valuation

Fair

Consensus price target signals moderate optimism; precise valuation metrics needed.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

BWXT delivered a record 2025 with strong Q4 performance, outsized growth in Commercial Operations, and a 50% YoY increase in total backlog. Strategic wins in HPDU, defense enrichment, AP1000, and CANDU, supported by recent acquisitions and facility buildouts, position the company for continued expansion. 2026 guidance calls for high-teens revenue growth and mid-teens EBITDA/EPS growth, with results weighted to the back half as new government programs ramp. While government margins will dip on mix in 2026, management expects recovery in 2027. Balance sheet flexibility improved via a 0% convertible, and liquidity is strong, underpinning continued investment and growth.

Growth

  • Full-year 2025: revenue +18%, adjusted EBITDA +15%, EPS +20%, free cash flow +16%, all above initial guidance
  • Backlog ended 2025 at $7.3B (+50% YoY); Commercial backlog $1.7B (+85% YoY, +16% sequential)
  • Q4 2025: revenue $886M (+19% YoY; organic +4%), adjusted EBITDA $148M (+13% YoY), adjusted EPS $1.08 (+17% YoY)
  • Commercial Operations Q4 revenue +95% YoY (organic +31%); segment adjusted EBITDA +87%; margin improved to 14.9%
  • BWXT Medical exceeded $100M annual revenue (~+20% YoY)
  • Commercial nuclear power book-to-bill >2 in Q4

Business Development

  • Completed acquisitions of AOT and Kinectrics; enabled $1.6B high-purity depleted uranium (HPDU) award and Kozloduy AP1000 owner’s engineer role
  • Secured new pricing agreements for naval propulsion equipment and fuel
  • Booked initial scopes to build U.S. defense uranium enrichment capability and expand HPDU production (NNSA)
  • Delivered first TRISO fuel core for Project Pele; manufacturing TRISO for Antares (target criticality by July 4, 2026)
  • Awardee on Missile Defense Agency’s $151B Shield (Golden Dome) IDIQ, positioning for infrastructure support and E&MT work
  • Assumed management and operations contract for Canadian Nuclear Laboratories (first international Technical Services project with Kinectrics)
  • Selected (with BWXT Laurentis/Canadian Nuclear Partners) as owner’s engineer for two AP1000 units at Bulgaria’s Kozloduy; actively bidding AP1000 component packages
  • Signed multiple SMR design/component contracts and a long-term CANDU fuel contract; strong CANDU aftermarket/services wins
  • Shipped two large steam generators for CVN 81 from the Mount Vernon, IN facility

Financials

  • 2025 adjusted effective tax rate 20.4% (Q4: 19.5% on R&D credit timing); 2026 expected ~22%
  • 2025 free cash flow $295M (Q4: $57M); operating cash flow +17% YoY
  • 2025 CapEx $185M (5.8% of sales); 2026 CapEx ~6% of sales
  • Government Ops Q4: revenue -1% YoY; adjusted EBITDA $111M; margin 18.8% (vs 2025 full-year 20.4%)
  • 2026 guidance: revenue ≈$3.75B (high-teens growth), adjusted EBITDA $645–$660M (low–mid-teens), non-GAAP EPS $4.55–$4.70 (mid–high teens), FCF $305–$320M
  • 2026 cadence: ~55% of EBITDA in 2H; Q1 EBITDA roughly flat YoY in Government; Commercial margins start below FY level and improve sequentially

Capital & Funding

  • Completed $1.25B 0% convertible debt offering; executed capped call raising effective conversion price to >$396
  • Proceeds used to repay credit facility and term loan; facilities renegotiated with improved terms and increased capacity
  • Year-end 2025 liquidity of $1.7B
  • Ongoing investments: centrifuge manufacturing development facility completed; designing new HPDU facility in Jonesborough, TN; Cambridge plant expansion; BWST Innovation Campus; BWXT Digital Center opened

Operations & Strategy

  • Priorities: execute robust backlog, process optimization, adopt digital/AI technologies, and pursue disciplined organic/inorganic growth
  • Ramping defense fuels (centrifuge enrichment) and HPDU programs; initial margins lower with improvement as milestones are met
  • Naval propulsion focus on long-lead materials, operational excellence, and deliveries; considering Mount Vernon expansion for U.S. commercial nuclear
  • AI/digital roadmap: ML for manufacturing quality control; democratizing LLM tools; advancing factory automation, digital twins, and digitized quality records (wireless constraints manageable in classified settings)
  • Positioned as a ‘super merchant supplier’ for SMR components; scaling medical isotopes (Tech-99 industrialization, actinium-225 modalities, lead-212 exploration)

Market & Outlook

  • Broad-based demand across government and commercial nuclear end-markets supports multi-year growth
  • 2026 segment outlook: Government Ops low–mid-teens growth (over half from defense fuels and HPDU); Commercial ~25% growth (low double-digit commercial power, high-teens medical, full-year Kinectrics)
  • Commercial Ops margin expected to improve ~100 bps in 2026; Government margin slightly lower in 2026 on mix, with rebound expected in 2027
  • Expect additional AP1000 component awards in 2026; continued momentum in CANDU refurbishments and SMR projects
  • Potential long-term tailwind from data center power needs favoring nuclear (not yet in current mix)

Risks Or Headwinds

  • 2026 Government Ops margin pressure from new program mix and infrastructure ramp; lower initial profit recognition
  • First quarter 2026 seasonality and mix to pressure margins; results back-half weighted (~55% EBITDA in 2H)
  • Higher 2026 effective tax rate (~22%) and slightly higher share count; lower pension/other income vs 2025
  • Execution risks on large new programs (defense fuels/HPDU, new facilities) and international projects
  • Classified environment constraints on wireless technologies may complicate digital deployments (management views as manageable)

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the BWXT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (BWXT)

© 2026 Stock Market Info — BWX Technologies, Inc. (BWXT) Financial Profile